17q12, explained for kidsdeletion syndrome · static snapshot
Adults Scientists Kids EN NL
Everything here was found on the internet and put together with help from a computer program that reads and writes (AI). It is here so you can learn — it is not the final word. Always check the real source. Read the whole notice
A number from a study Kidneys and diabetes 1 supporting source confidence 97% novelty 60%

One French study systematically evaluated the use of SU or repaglinide after the genetic diagnosis at a median [IQR] dur

A source reports “29 of 51” in the context of diabetes metabolic: “One French study systematically evaluated the use of SU or repaglinide after the genetic diagnosis at a median [IQR] duration of 0.75 [0-5.25] years and reported that 29 of 51 (57%) patients displayed an HbA1c decrease.”

More a number from a study

How this was derived

Numbers are quoted verbatim from the source; check the source before quoting onward.

Generated 2026-11-13, last changed yesterday. Dedup key freq:29 of 51. The engine re-checks this insight on every analysis run; if more sources agree, its corroboration and confidence go up and it reappears as “new”.

Evidence (1 quote)

Precision treatment of beta-cell monogenic diabetes: a systematic review peer_reviewed · published 2024-01-01 · live page
One French study systematically evaluated the use of SU or repaglinide after the genetic diagnosis at a median [IQR] duration of 0.75 [0-5.25] years and reported that 29 of 51 (57%) patients displayed an HbA1c decrease.

Supporting documents (1)

StorySourcePublishedSeenRelevance
Precision treatment of beta-cell monogenic diabetes: a systematic review pmc 2024-01-01 yesterday 1.00